A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2017
At a glance
- Drugs PLX R18 (Primary)
- Indications Haematological disorders
- Focus Adverse reactions
- Sponsors Pluristem Therapeutics
- 23 Feb 2017 Status changed from not yet recruiting to recruiting.
- 15 Nov 2016 According to a Pluristem media release, Dr. Hillard Lazarus of Case Western Reserve University has been appointed as the Principal Investigator of this trial.
- 14 Sep 2016 According to a Pluristem media release, company expects to initiate this study in the coming months by the end of 2016.